Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

StockNews.com

Which of these 3 Pharma Stocks Should You Buy, Hold or Sell?

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. So, let's analyze whether Johnson & Johnson (JNJ), Calliditas Therapeutics AB (CALT), and Aurora Cannabis (ACB) are a Buy, Hold, or Sell.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks Surpassing Johnson & Johnson (JNJ)

The pharmaceutical sector is anticipated to thrive as demand grows and technology advances. While Johnson & Johnson (JNJ) receives much attention from investors, I believe Horizon Therapeutics Public Limited (HZNP), Dr. Reddy’s Laboratories (RDY), and Novartis (NVS) are better investments right now. Read on.

StockNews.com

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

Barchart

3 Pharma Stocks to Consider Prescribing to for Quality

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given the solid long-term prospects of the industry, investors should consider buying quality stocks, Johnson & Johnson (JNJ), AstraZeneca (AZN), and Dr. Reddy’s Laboratories (RDY). Read on.

StockNews.com

Is Johnson & Johnson (JNJ) a Buy Before September Begins?

Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Pharma Stocks With Promising Pipelines

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

StockNews.com

3 Dividend Kings To Buy And Hold Forever in a Retirement Portfolio

Looking for ideas in your financial freedom or retirement portfolio? Here's 3 stocks that fit the bill.

Barchart

3 Pharma Stock Buys You Don’t Want to Miss

The pharmaceutical industry is growing amid robust demand. Also, given that healthcare stocks are generally thought of as defensive investments, fundamentally strong Johnson & Johnson (JNJ), Novo Nordisk (NVO), and AstraZeneca (AZN) might be profitable buys now. Read on.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

StockNews.com

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

StockNews.com

Top 3 Pharma Stocks You Can’t Miss out On

The ever-transforming pharmaceuticals sector is ready to seize the opportunity to address the growing demand for healthcare across the globe. Therefore, adding these three quality pharma stocks, Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Dr. Reddy's Laboratories (RDY), to your portfolio could prove to be beneficial. Read…

StockNews.com

Which Pharma Stock Is the Better July Pick: Johnson & Johnson (JNJ) or Curaleaf Holdings (CURLF)?

On the backs of increasing medical requirements amid the soaring incidence of chronic diseases, the pharmaceutical industry’s outlook radiates promise. Given this backdrop, let us compare pharma stocks Johnson & Johnson (JNJ) and Curaleaf Holdings (CURLF) to discover which one of these could be worth buying in July. Read on….

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Medical Stock Picks for Investors

As the demand for healthcare products and solutions continues to rise, the medical industry is poised for remarkable growth. Therefore, quality medical stocks Johnson & Johnson (JNJ), AstraZeneca (AZN), and Astellas Pharma (ALPMY) could be the ideal investments for your portfolio amid current market uncertainties. Read on….

Barchart

3 Dividend Kings to Buy if Times Get Tough

The United States has yet to enter a recession, but even if we continue in this downturn or come out of it, these three Dividend Kings are top performers to consider.

StockNews.com

Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell?

Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.

Kiplinger

Johnson & Johnson Spins Off Kenvue in Biggest IPO Haul Since 2021

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

Barchart

The Fed Is About To Raise Rates! Get Ready To Plan Your Next Move!

Here Are 2 Ideas Depending on How the Next Fed Announcement Goes.

StockNews.com

Investors Are Keeping This Healthcare Stock Long-Term

Despite an uncertain macro environment, healthcare giant Johnson & Johnson (JNJ) reported outstanding results in 2022, reflecting its business segments' continued strength. Moreover, the company has a history of increasing dividends for 60 consecutive years. Given its sustained business momentum and steady dividend payments, investors seem to stay committed to…

Barchart

Here's 3 Dividend Companies That Just Crossed Above Their 50 Moving Average

Trading Smarter, Not Harder With the 50-Day Moving Average Strategy

1 … 6 7 8 9

People

Mangeet Kaur BounsMangeet

595 stories

Steve Reitmeister

508 stories

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.